Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,500
Single User License Price INR 135
Corporate User License Price USD 7,500
Corporate User License Price INR 472
Site License Price USD 5,000
Site License Price INR 337
Request a Quote

Report Title

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,500
Site License USD 5,000
Enterprise Wide License USD 7,500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018



Executive Summary

Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

 

Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Non-Hodgkin Lymphoma (Oncology) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 4, 30, 160, 136, 1, 5, 126, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules, respectively.

 

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 13

Non-Hodgkin Lymphoma - Overview 14

Non-Hodgkin Lymphoma - Therapeutics Development 15

Non-Hodgkin Lymphoma - Therapeutics Assessment 108

Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 134

Non-Hodgkin Lymphoma - Drug Profiles 255

Non-Hodgkin Lymphoma - Dormant Projects 2088

Non-Hodgkin Lymphoma - Discontinued Products 2113

Non-Hodgkin Lymphoma - Product Development Milestones 2122

Appendix 2133

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AlfaSigma SpA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aptevo Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Autolus Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Brickell Biotech Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellestia Biotech AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cerenis Therapeutics Holding SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cielo Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

ACEA Biosciences Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Affimed GmbH

Affitech A/S

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

AlfaSigma SpA

Allinky Biopharma

Altor BioScience Corp

Amgen Inc

Angimmune LLC

Aptevo Therapeutics Inc

arGEN-X BV

Ariad Pharmaceuticals Inc

ArQule Inc

Arrien Pharmaceuticals LLC

Arven Ilac

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Autolus Ltd

Bantam Pharmaceutical LLC

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Bio-Path Holdings Inc

Biocon Ltd

Biogen Inc

BioInvent International AB

BioLineRx Ltd

BioSight Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Cell Source Inc

Cell>Point LLC

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Celltrion Inc

Cellular Biomedicine Group Inc

Centrose LLC

Cerenis Therapeutics Holding SA

CerRx Inc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Clevexel Pharma SAS

Corvus Pharmaceuticals Inc

CrystalGenomics Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Curis Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Denovo Biopharma LLC

Dynavax Technologies Corp

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Epizyme Inc

Erytech Pharma SA

Eureka Therapeutics Inc

Evotec AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

Formula Pharmaceuticals Inc

Forty Seven Inc

Fujifilm Holdings Corporation

Galderma SA

Gamida Cell Ltd

Genentech Inc

Genor BioPharma Co Ltd

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Grupo Ferrer Internacional SA

GT Biopharma Inc

H3 Biomedicine Inc

Heidelberg Pharma AG

Hualan Biological Engineering Inc

Hutchison MediPharma Ltd

IGF Oncology LLC

Ignyta Inc

Immune Design Corp

ImmunGene Inc

ImmunoGen Inc

Immunomedics Inc

Immunomet Therapeutics Inc

Immunovaccine Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

IO Biotech ApS

Japan Tobacco Inc

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

K-Stemcell Co Ltd

KAHR medical Ltd

Kainos Medicine Inc

Karyopharm Therapeutics Inc

Kiromic Inc

Kite Pharma Inc

Klyss Biotech Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

Leadiant Biosciences Inc

Les Laboratoires Servier SAS

LFB SA

Loxo Oncology Inc

LSK BioPartners Inc

Mabion SA

MacroGenics Inc

Meabco AS

MedImmune LLC

Medivir AB

MEI Pharma Inc

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Miragen Therapeutics Inc

Mirati Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Molecular Templates Inc

Moleculin Biotech Inc

Morphogenesis Inc

MorphoSys AG

NantKwest Inc

NBE-Therapeutics AG

Nerviano Medical Sciences Srl

Neumedicines Inc

Nichi-Iko Pharmaceutical Co Ltd

Nordic Nanovector ASA

NovaLead Pharma Pvt Ltd

Novartis AG

NovImmune SA

Oncobiologics Inc

Onconova Therapeutics Inc

Oncopeptides AB

Oncovir Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Oxford BioTherapeutics Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Philogen SpA

PIQUR Therapeutics AG

Plexxikon Inc

Portola Pharmaceuticals Inc

Prescient Therapeutics Ltd

Protheragen Inc

Quimatryx SL

Rafael Pharmaceuticals Inc

Refuge Biotechnologies Inc

Regeneron Pharmaceuticals Inc

Respiratorius AB

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sandoz International GmbH

Sanofi

Sareum Holdings Plc

Seattle Genetics Inc

Selvita SA

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Henlius Biotech Co Ltd

Shanghai Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Sierra Oncology Inc

Solasia Pharma KK

Soligenix Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sunesis Pharmaceuticals Inc

Supratek Pharma Inc

Surface Oncology Inc

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takara Bio Inc

TCR2 Therapeutics Inc

Teva Pharmaceutical Industries Ltd

TG Therapeutics Inc

TRACON Pharmaceuticals Inc

Transgene Biotek Ltd

Transgene SA

Trillium Therapeutics Inc

Triphase Accelerator Corp

Trovagene Inc

TTY Biopharm Company Ltd

United BioPharma Inc

Unum Therapeutics Inc

Verastem Inc

Vivolux AB

Vyriad Inc

Xencor Inc

Zhejiang Hisun Pharmaceutical Co Ltd

ZIOPHARM Oncology Inc

Non-Hodgkin Lymphoma Therapeutic Products under Development, Key Players in Non-Hodgkin Lymphoma Therapeutics, Non-Hodgkin Lymphoma Pipeline Overview, Non-Hodgkin Lymphoma Pipeline, Non-Hodgkin Lymphoma Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand